From: Four screening instruments for frailty in older patients with and without cancer: a diagnostic study
With and without cancer (%) | With cancer (%) | Without cancer (%) | With and without cancer (%) | With and without cancer (%) | |
---|---|---|---|---|---|
aCGA | CUT-OFF ≥ 1 | CUT-OFF ≥ 2 | |||
Sensitivity | 85 (81 – 88) | 79 (71 – 87) | 87 (83 – 91) | 58 (53 – 63) | |
Specificity | 63 (58 – 68) | 59 (50 – 68) | 64 (59 – 70) | 94 (91 – 96) | |
PPV | 68 (64 – 73) | 64 (55 – 73) | 70 (65 – 75) | 90 (87 – 93) | |
NPV | 82 (78 – 85) | 75 (67 – 83) | 84 (80 – 88) | 70 (66 – 75) | |
Classified as frail | 60 | 59 | 61 | 31 | |
VES-13 | CUT-OFF ≥ 3 | CUT-OFF ≥ 2 | CUT-OFF ≥ 4 | ||
Sensitivity | 78 (74 – 82) | 67 (58 – 76) | 82 (77 – 86) | 81 (77 – 85) | 74 (70 – 78) |
Specificity | 76 (72 – 80) | 70 (61 – 78) | 79 (74 – 83) | 69 (65 – 74) | 78 (74 – 82) |
PPV | 75 (71 – 80) | 67 (58 – 76) | 78 (73 – 83) | 71 (67 – 76) | 76 (72 – 80) |
NPV | 78 (74 – 82) | 70 (61 – 78) | 82 (77 – 86) | 79 (75 – 83) | 76 (72 – 80) |
Classified as frail | 50 | 48 | 51 | 55 | 47 |
GFI | CUT-OFF ≥ 4 | CUT-OFF ≥ 3 | CUT-OFF ≥ 5 | ||
Sensitivity | 76 (71 – 86) | 79 (61 – 87) | 74 (69 – 79) | 88 (84 – 91) | 59 (54 – 63) |
Specificity | 73 (68 – 77) | 71 (63 – 80) | 73 (68 – 78) | 49 (44 – 54) | 83 (79 – 87) |
PPV | 72 (68 – 77) | 72 (63 – 80) | 72 (67 – 78) | 62 (57 – 67) | 76 (72 – 81) |
NPV | 76 (72–80) | 78 (71 – 86) | 75 (70 – 80) | 81 (77 – 85) | 68 (63 – 73) |
Classified as frail | 51 | 53 | 50 | 69 | 37 |
G8 | CUT-OFF ≤ 14 | CUT-OFF ≤ 13 | CUT-OFF ≤ 15 | ||
Sensitivity | 78 (74 – 82) | 87 (80 – 93) | 75 (70 – 80) | 61 (56 – 65) | 96 (94 – 98) |
Specificity | 68 (63 – 72) | 64 (55 – 73) | 69 (64 – 74) | 86 (82 – 89) | 39 (34 – 44) |
PPV | 70 (65 – 74) | 69 (61 – 78) | 70 (64 – 75) | 80 (76 – 84) | 60 (55 – 65) |
NPV | 77 (73 – 81) | 84 (77 – 91) | 75 (70 – 80) | 70 (65 – 74) | 91 (88 – 94) |
Classified as frail | 55 | 60 | 52 | 37 | 78 |